Abstract :
Keywords Neonate; Inotropes; Vasoactive; Outcomes Highlights * VIS is a weighted sum of vasopressors/inotropes, indicating cardiovascular support burden. * Death/severe neuroinjury was associated with lower GA and higher VIS.sup.max. * VIS.sup.max [greater than or equal to] 20 within 48 h of treatment initiation may identify high risk patients. Abstract Background Vasoactive-Inotropic Score (VIS) is a weighted sum of various vasopressors and inotropes; its utility among preterm neonates is understudied. Objective To investigate the association between maximum VIS (VIS.sup.max) during the first 12, 24 and 48 h of treatment among preterm neonates who received vasopressors/inotropes, and the composite outcome of death/severe neuroinjury (sNI). Methods Retrospective cohort study, over 6-years, including neonates Results 192 infants (mean GA and birth weight 26.8 [plus or minus] 3.3 weeks and 952 [plus or minus] 528 g, respectively) were included. The most common primary diagnosis was sepsis/necrotizing enterocolitis (69 %). Median VIS for the entire cohort was 10. Death/sNI was associated with lower GA at birth and treatment, as well as higher frequency of VIS.sup.max of 10--19 or [greater than or equal to]20, compared to Conclusions Vasoactive-Inotropic Score may be a valid measure to quantify cardiovascular support in preterm infants needing hemodynamic support. Maximum VIS [greater than or equal to]20 within 48 h of treatment initiation may identify patients at high risk of adverse outcomes. Author Affiliation: (a) Department of Paediatrics, Mount Sinai Hospital, Toronto, ON, Canada (b) Department of Paediatrics, University of Toronto, Toronto, ON, Canada (c) Queen's University, Kingston, ON, Canada (d) Department of Respiratory Therapy, Mount Sinai Hospital, Toronto, ON, Canada (e) Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, ON, Canada (f) Clinic of Neonatology, Lausanne University Hospital, Lausanne, Switzerland (g) Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada * Corresponding author at: Mount Sinai Hospital, Rm 19-231J, 600 University Avenue, Toronto, ON M5G 1X5, Canada. Article History: Received 7 June 2022; Revised 12 August 2022; Accepted 15 August 2022 Byline: Ashraf Kharrat [ashraf.kharrat@sinaihealth.ca] (a,b,*), Gabriella Ripstein (c), Michelle Baczynski (d), Faith Zhu (b), Xiang Y. Ye (e), Sebastien Joye (f), Amish Jain (a,b,g)